Key Takeaways
- Shares of Relmada Therapeutics climbed approximately 31% during pre-market hours Monday following dual positive announcements
- Phase 2 interim results for NDV-01 in bladder cancer demonstrated a 76% complete response rate at 12 months
- An oversubscribed $160 million private investment in public equity (PIPE) was completed at $4.75 per share
- The financing package consists of 29.47 million shares plus pre-funded warrants for 4.21 million additional shares, set to close March 11
- Analysts maintain a Strong Buy rating on RLMD stock with a consensus price target of $10.25
The initial catalyst came from interim results of the company’s Phase 2 study evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC). Data revealed a 12-month complete response rate reaching 76%, accompanied by a well-tolerated safety profile. Notably, this response rate was achieved in the BCG-unresponsive patient subset as well.
Dr. Raj S. Pruthi, serving as Chief Medical Officer of Oncology at Relmada, described these findings as providing “meaningful clinical validation” for the development program.
Relmada Therapeutics, Inc., RLMD
Management indicated plans to move NDV-01 forward into a registrational Phase 3 clinical program dubbed RESCUE, which will pursue two distinct development tracks: one focusing on BCG-unresponsive cases and another targeting adjuvant therapy in intermediate-risk patients. The Phase 3 trial initiation is anticipated around mid-2026.
Company Secures $160 Million in Private Financing
Concurrent with releasing the clinical data, Relmada disclosed the pricing of an oversubscribed $160 million private placement transaction.
The financing structure includes 29,474,569 shares of common stock at a price of $4.75 per share, along with pre-funded warrants covering 4,210,527 additional shares at $4.749 each with a minimal exercise price of $0.001.
Jefferies, Leerink Partners, Piper Sandler, and Mizuho serve as placement agents for the transaction. The offering is scheduled to close on March 11, 2026, pending satisfaction of customary closing conditions.
The capital raised will be allocated toward general working capital needs and the continued advancement of the company’s research and development pipeline.
Investors participating in the placement received resale registration rights. The company has agreed to meet specific SEC filing timelines, with potential liquidated damages of 1.0% for each 30-day delay period, subject to specified caps.
Share Price Performance
RLMD stock advanced 31.01% in pre-market activity on Monday. The shares had already posted modest gains in the previous trading session on Friday.
Despite Monday’s surge, the stock remains down 7.87% for the year-to-date period. Looking at a longer timeframe, shares have delivered impressive returns of 1,536% over the trailing 12 months.
Trading activity exploded following the announcements. Volume exceeded 7.9 million shares on Monday, significantly above the three-month average daily volume of approximately 570,000 shares.
This volume spike — more than 13 times the typical daily average — underscores the substantial market interest generated by the clinical data release and financing announcement.
Current Wall Street consensus on RLMD stock stands at Strong Buy, supported by four Buy recommendations published within the last three months.
The mean analyst price target is $10.25, implying potential upside of approximately 130% from recent trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
